The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi by Luminari, Stefano et al.
Annals of Oncology 24: 2108–2112, 2013
doi:10.1093/annonc/mdt137
Published online 12 April 2013
The use of FDG-PET in the initial staging of 142
patients with follicular lymphoma: a retrospective study
from the FOLL05 randomized trial of the Fondazione
Italiana Linfomi
S. Luminari1*, I. Biasoli2, L. Arcaini3, A. Versari4, C. Rusconi5, F. Merli6, M. Spina7, A. J. M. Ferreri8,
P. L. Zinzani9, A. Gallamini10, S. Mastronardi1, C. Boccomini11, G. Gaidano12, A. M. D’Arco13,
F. Di Raimondo14, A. M. Carella15, A. Santoro16, P. Musto17 & M. Federico1
1Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy; 2Department of Medicine, University Hospital
and School of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; 3Department of Hematology Oncology, Fondazione IRCCS Policlinico San
Matteo & Department of Molecular Medicine, University of Pavia, Pavia; 4Department of Nuclear Medicine, Arcispedale S. Maria Nuova Hospital IRCCS, Reggio Emilia;
5Division of Hematology, Department of Hematology and Oncology, Niguarda Hospital, Milan; 6Hematology Unit, Arcispedale S. Maria Nuova Hospital IRCCS, Reggio
Emilia; 7Oncology Unit A, Division of Medical Oncology A, National Cancer Institute, Aviano; 8Unit of Lymphoid Malignancies, Department of Onco-Hematology, San
Raffaele Scientiﬁc Institute, Milan; 9Institute of Hematology and Medical Oncology ‘L. & A. Seràgnoli’, Bologna; 10Hematology Unit, S. Croce e Carle Hospital, Cuneo;
11SC Ematologia 2, AO Cittá della Salute e della Scienza, Turin; 12Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern
Piedmont, Novara; 13Onco-Ematologia Nocera Inf-Pagani, Nocera Inferiore; 14Division of Hematology, Ospedale Ferrarotto, AOU Policlinico-OVE, University of Catania,
Catania; 15U.O.C Ematologia 1, IRCCS San Martino-IST, Genova; 16Department of Oncology and Hematology, Humanitas Cancer Center, Rozzano; 17Department of
Onco-Hematology, IRCCS-CROB, Rionero in vulture, Potenza, Italy
Received 20 December 2012; revised 28 February 2013; accepted 1 March 2013
Background: The role of [18F] ﬂuorodeoxyglucose (FDG)-positron emission tomography (PET) in follicular lymphoma
(FL) staging is not yet determined.
Patients and methods: The aim of the present study was to investigate the role of PET in the initial staging of FL
patients enrolled in the FOLL05-phase-III trial that compared ﬁrst-line regimens (R-CVP, R-CHOP and R-FM). Patients
should have undergone conventional staging and have available PET baseline to be included.
Results: A total of 142 patients were analysed. PET identiﬁed a higher number of nodal areas in 32% (46 of 142) of
patients and more extranodal (EN) sites than computed tomography (CT) scan. Also, the Follicular Lymphoma
International Prognostic Index (FLIPI) score increased in 18% (26 of 142) and decreased in 6% (9 of 142) of patients.
Overall, the impact of PET on modifying the stage was highest in patients with limited stage. Actually, 62% (15 of 24) of
cases with limited disease were upstaged with PET.
Conclusions: The inclusion of PET among staging procedures makes the evaluation of patients with FL more
accurate and has the potential to modify therapy decision and prognosis in a moderate proportion of patients. Further
prospective clinical trials on FL should incorporate PET at different moments, and the therapeutic criteria to start
therapy should be re-visited in the views of this new tool.
Key words: follicular lymphoma, FDG-PET, staging, CT scan
introduction
Follicular lymphoma (FL) accounts for about 10%–20% of
lymphomas in western countries and is the most frequent of
indolent lymphomas. Although patients with FL achieve
excellent response with initial treatment, most of them relapse
with median progression-free survival of 60 months and a
variable clinical course [1].
[18F]ﬂuorodeoxyglucose (FDG)-positron emission
tomography (PET) recently emerged as a powerful functional
imaging tool in staging and response assessment in Hodgkin’s
lymphoma and diffuse large B-cell lymphoma [2, 3]. FL is a
[18F]-FDG avid disease; more than 90% of patients show a PET
positive at presentation and sensitivity of staging PET is
usually >95% [4–7]. Despite this, the literature concerning the
role of PET in FL staging is scarce, and this tool is not
recommended as a routine procedure [3]. In a retrospective
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analysis on 22 patients, PET was able to detect more nodal and
extranodal (EN) lesions than computed tomography (CT) scan
[8]. Moreover, the use of PET can result in a modiﬁcation of
initial staging in up to one-third of patients [9–12]. Recent
data from a large multicentre clinical trial in advanced FL
patients (PRIMA trial) showed that the PET status at the end
of immunochemotherapy is strongly predictive of outcome
[13, 14]. Furthermore, the potential modiﬁcation of initial
stage by PET could be associated with both a change in
therapeutic choice and overall prognosis.
In 2005, the Fondazione Italiana Linfomi (FIL) started the
FOLL05 prospective, randomized trial (NCT00774826) that
compared three chemoimmunotherapy regimens (R-CVP,
R-CHOP and R-FM) as ﬁrst-line treatment for patients with
stage II/IV FL [15]. Although PET was not included among
diagnostic procedures, several patients underwent PET scan for
initial staging. Taking this into consideration, we investigated
the role of PET in the initial staging of patients with FL by
comparing PET-based staging with the conventional CT-based
Ann Arbor staging.
patients and methods
inclusion and exclusion criteria
The study was designed as a retrospective analysis on patients with FL who
were enrolled in the FOLL05 phase III trial (NCT00774826), which
compared three chemoimmunotherapy regimens as ﬁrst-line treatment
(R-CVP, R-CHOP and R-FM regimens). As this study is based on an
unplanned analysis of the FOLL05, a speciﬁc protocol was approved by ethics
committee and patients were required to sign an informed consent form.
In order to be considered for the current study, patients were required to
be randomly assigned in the FOLL05 trial, who are between 18 and 75
years, have Ann Arbor stage II–IV, and have active disease [16]. For the
purposes of the present study, patients should also have available data on
baseline CT scan (B-CT) with iodine contrast medium for neck, thorax and
abdomen, and on baseline total-body PET/CT scan (B-PET). B-PET was
allowed if available by the FOLL05 procedures but not mandatory. Most of
the patients did not undergo a baseline PET because of reimbursement
issues and logistic reasons. Both B-CT and B-PET were to be carried out
before treatment start, time between the B-PET and B-CT should not
exceed 3 months, no surgical procedures were allowed during the period
elapsed between the two examinations and explored regions should be
comparable regarding extension. Finally, all patients were also required to
have available details on clinical presentation, treatment and follow-up.
data collection and analysis plan
Patients were identiﬁed with the original Id number of the FOLL05. Data
on clinical presentation, treatment and follow-up were retrieved from the
existing dataset of the randomized protocol: histology with grading
according to the current REAL-WHO classiﬁcation, demographics, Ann
Arbor stage, bone marrow (BM) biopsy and laboratory parameters.
For speciﬁc study purposes, data were collected on each B-PET or B-CT
scan based on the original report of the examination. B-CT and B-PET were
reviewed by SL, AV and MQ and discussed with the nuclear physician. We
considered as positive all lesions that were described as positive in the local
report. PET analysis was based on a qualitative assessment of PET results
and no data were available on functional ﬁndings.
For staging assessment, disease extension at baseline was estimated
independently for both PET and CT. The conventional and reference stage
was deﬁned with CT and BM only [17]. For each examination, nodal sites
were classiﬁed and counted accordingly to the Follicular Lymphoma
International Prognostic Index (FLIPI) schema [18] Nodal sites were
considered positive if their maximum transverse diameters were >1.5 cm at
CT or if they were positive at PET scan. EN sites were considered positive
at CT in the case of nodular involvement or case of organ enlargement not
otherwise justiﬁed. EN involvement at PET scan was considered for sites
showing avidity for FDG. EN sites were counted on an organ basis. BM
involvement was established on the basis of the local pathology report of
BM biopsy.
statistical analysis
Statistical analysis was carried out with SPSS software (Chicago, IL) and
Stata. Standard descriptive analyses were carried out. In order to evaluate
the agreement between CT and PET results regarding the number of nodal
sites, the number of EN sites, Ann Arbor Staging and FLIPI score, Cohen’s
kappa statistic was used. The level of agreement was deﬁned by Koch–
Landis scale [19].
results
One hundred and ninety-nine outpatients were initially
identiﬁed for this study. Subsequently, 57 patients were
excluded due to violation of the inclusion criteria. The
remaining 142 patients fulﬁlled the eligibility criteria and were
considered for this study. Using the original FOLL05 data, the
two groups were well balanced regarding stage and FLIPI score
(data not shown).
The median age was 57 years (range 33–74). Patients’
characteristics at diagnosis are shown in Table 1. FDG avidity
Table 1. Patients’ characteristics
Feature n = 142 (%)
Gender
Male 69 (49)
Female 73 (51)
Ann Arbor stage (CT + BM)
I–II 25 (18)
III 37 (26)
IV 80 (56)
Bulky disease
No 82 (58)
Yes 57 (40)
Missing 3 (2)
BM inﬁltration
No 72 (51)
Yes 70 (49)
β2-microglobulin
≤1 unl 68 (48)
>1 unl 73 (51)
Missing 1 ( 1)
FLIPI
0–1 45 (32)
2 53 (37)
3–5 44 (31)
FLIPI, Follicular Lymphoma International Prognostic Index; BM, bone
marrow; CT, computed tomography; UNL, upper normal limit.
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was demonstrated in 98% (139 of 142) of patients. These FDG-
negative cases were related to low-grade FL.
nodal areas
PET allowed the identiﬁcation of more nodal areas than CT
scan in 32% (46 of 142) of the patients. In fact, 39%, 39% and
22% of cases presented with <4, 4–7 and >7 nodal areas,
respectively, at CT scan. Using PET, 28%, 37% and 35% of
cases presented with <4, 4–7 and >7 nodal areas, respectively.
PET identiﬁed a lower number of nodal areas in only 15 (11%)
patients. The agreement between PET and CT scan was
considered fair (κ = 0.37, Table 2).
FLIPI score
Using PET, the FLIPI score was increased in 26 (18%) patients
and decreased in 9 (6%). In fact, 32%, 37% and 31% of patients
were classiﬁed by CT with a score of 0–1, 2 and 3–5,
respectively. Using PET, 25%, 40% and 35% of cases were
classiﬁed with a score of 0–1, 2 and 3–5, respectively. The
agreement between PET and CT scan for FLIPI was considered
substantial (κ = 0.62, Table 2).
staging
Initial PET had an impact on Ann Arbor staging. A proportion
of 17% (24 of 139) and 83% (115 of 139) of FDG avidly
patients were classiﬁed by CT as stage II and III–IV,
respectively. On the other hand, 10% (14 of 139) and 90% (125
of 139) of patients were classiﬁed by PET as stage II and
III–IV, respectively. Fifteen (11%) patients were up-staged with
PET, while only ﬁve (1%) were down-staged. Moreover, 15
(62%) of the 24 patients previously classiﬁed as stage II were
classiﬁed by PET as having stage III–IV (Table 3).
The agreement between PET and CT scan for staging
purposes was considered fair when the information on
histology of BM was not taken into account, and it improved
to moderate (κ = 0.62) when this information was considered
(Table 3).
extranodal sites
Overall, CT scans allowed the identiﬁcation of 60 extranodal
sites (ENSs) in 47 patients, 2 or more were described in 12
patients; the most frequent were spleen, liver and
gastrointestinal (GI) tract. PET allowed the identiﬁcation of 97
ENSs in 67 patients and 2 or more ENSs were found in 21
patients; the most frequent were bone, spleen and GI tract
(Table 4). PET detected bone lesions in 34 patients. In these 34
patients, BM involvement was detected in 71% of the patients
(24 of 34). In the group of 108 patients without PET detected
bone lesions, BM involvement was detected in 43% (46 of 108).
Overall PET and BMB were concordant in 85 of 142 cases with
a fair concordance (κ = 0.2).
Table 2. Number of nodal areas and FLIPI score
Nodal areas FLIPI score
CT scan CT scan
<4 4–7 >7 Total 0–1 2 3–5 Total
PET scan <4 30 10 0 40 PET scan 0–1 29 4 2 35
4–7 23 25 5 53 2 15 39 3 57
>7 3 20 26 49 3–5 1 10 39 50
Total 56 55 31 142 Total 45 53 44 142
κ 0.37 0.62
Agreement 57% 75%
FLIPI, Follicular Lymphoma International Prognostic Index; PET, positron emission tomography; CT, computed tomography.
Table 3. Ann Arbor stage without bone marrow histopathology and with bone marrow histopathology (n = 139 patients with baseline-positive positron
emission tomography)
Without BM histopathology With BM histopathology
CT scan CT scan
I II III IV Total I II III IV Total
PET scan I 0 1 3 0 4 PET Scan I 0 1 1 0 2
II 0 11 3 1 15 II 0 8 3 1 12
III 1 9 57 5 72 III 1 8 27 3 39
IV 0 10 21 17 48 IV 0 6 6 74 86
Total 1 31 84 23 139 Total 1 23 37 78 139
κ 0.36 0.62
Agreement 61% 78%
BM, bone marrow; PET, positron emission tomography.
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discussion
Emerging data regarding the role of PET in the management
of FL patients were recently published [6, 8, 13, 14, 20].
However, the literature regarding the role of PET in staging of
FL patients is scarce. In the present study, we sought to
investigate if there is an impact of PET on staging in a
retrospective analysis of patients included in the FOLL05
multicentre randomized clinical trial conducted in 60 centres
in Italy. To our knowledge, it is one of the largest multicentre
cohorts of FL patients that addressed this issue. The main
ﬁndings of this analysis were that PET can detect more nodal
and EN sites than CT scan, yielding a moderate stage
migration. PET was also able to modify FLIPI, but the
prognostic impact and clinical relevance of these ﬁndings are
not yet clear.
Overall, the impact of PET on modifying the stage was
highest in patients with limited stage. Actually, in our series
62% of cases with limited disease were upstaged with PET.
Regarding patients with advanced stage, although PET was able
to identify more sites than CT scan, the impact in modifying
staging was less apparent and in most cases neutralized by the
information of BM biopsy. Upstaging of localized disease could
have relevant therapeutic and clinical implications. Currently, a
therapeutic approach for limited stage FL patients is involved-
ﬁeld radiation therapy which yields long-term freedom from
progression in half of the patients, with most relapses
occurring outside the irradiated volume [21]. Although our
ﬁndings must be validated by other studies speciﬁcally focused
on limited stage FL, they are clear enough to recommend more
accurate staging procedures, including PET at least in patients
for whom involved ﬁeld radiation therapy are an option.
In addition to stage migration, the high accuracy of PET in
describing nodal sites may have implications regarding
prognostic assessment. The number of nodal sites is one of the
prognostic factors of the FLIPI score, which has been available
for more than 5 years and is currently an important tool for
treatment planning in FL [18]. Based on our results, the
agreement between the FLIPI calculated with CT and PET was
substantial and 75% of patients were allocated to the same risk
group by the two techniques. Whether the outcome of the
remaining 25% of the patients is better foreseen by PET or not
deserves further investigation. FLIPI-2 is another validated tool
to assess prognosis of patients with FL and that do not include
the number of nodal sites and is not affected by PET results [22].
PET was also able to detect more EN sites than CT,
particularly bones. Also, the concordance of PET and CT for
different organs was only moderate for spleen, skin and soft
tissue, and only fair and slight for others. If we take into
consideration the GELF criteria for starting treatment, the
information of PET regarding EN sites could change the
approach in a small group of patients. This point should be
considered carefully because we cannot exclude the possibility
that some unusual sites may represent, in fact, false-positive
END sites. Moreover, PET was not useful in detecting BM
inﬁltration and no data are currently available to omit BM
biopsy among initial staging procedures in all patients with FL.
We are aware that one limitation of the present study was its
retrospective nature. Nevertheless, a selection bias is unlikely
because although PET was not mandatory among the staging
procedures of the FOLL05 clinical trial, it was recommended in
all centres where the facility was available. Also, the clinical
information was prospectively collected, except for the PET
results. Another aspect that should be raised is the use of
routine visual assessment practices for PET interpretation.
Observer variation in the interpretation of imaging studies can
be substantial, and the reasons might differ depending on each
method. One could argue that disagreement between CT and
PET could not be only explained by the fact that PET detects
more sites than CT but it is also related, at least in multicentric
retrospective studies like this one, to a lack of standardization
of CT reporting.
Finally, our analysis was based on a qualitative “anatomic”
assessment of PET results and no data were available on
functional ﬁndings. As observed in diffuse large B cell
lymphomas, the rate of metabolic activity of disease measured
by SUV and SUV max seems to add important information
mainly in terms of prognosis [23]. The baseline SUV has not
been extensively studied in FL patients so far, but it is likely
that in terms of SUV, assessment requires accurate and
standardized procedures and requires well-designed
prospective studies.
In conclusion, based on our results, the inclusion of PET
among staging procedures makes the evaluation of patients
with FL more accurate and has the potential to modify therapy
decision and prognosis in a moderate proportion of patients.
Further prospective clinical trials on FL should incorporate
PET at different moments, and the therapeutic criteria to start
therapy should be re-visited in the views of this new tool.
Taken together, the results of our study support the claim for
the need of a consensus to include PET scanning among
staging procedures in FL.
acknowledgements
This work was partly supported by the ‘Associazione Angela
Serra per la ricerca sul cancro’, Modena, Italy
Table 4. Extranodal (EN) sites identiﬁed by computed tomography (CT)
scan and positron emission tomography, PET
CT (n = 60) PET (n = 97) κ
Spleen 31 26 0.49
Bone 3 34 0.07
Liver 8 2 0.18
Skin and soft tissues 5 12 0.44
Gastrointestinal (GI) tract 2 9 0.35
Others 11* 14* NA
*Others in CT include tonsil, gall bladder, thyroid, pleura, adrenal, lung,
peritoneum, ocular adnexal, parotid, nasopharynx, gluteal muscle (each
n = 1).
Others in PET include pleura (n = 3), lung (n = 2), parotid (n = 2), ocular
adnexal, nasopharynx, glands, laryngeal, adrenal, utero and thyroid (each
n = 1).
NA, not applicable.
Annals of Oncology original articles
Volume 24 | No. 8 | August 2013 doi:10.1093/annonc/mdt137 | 
 at U
niversitÃ degli Studi di M
odenae Reggio Emilia on December 9, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
funding
This work was supported by an Italian Ministry of Health
national grant RF-CRB-2008-1146343 of the ‘Bando Ricerca
Finalizzata 2008’ assigned to Rionero in Vulture, Italy.
disclosure
The authors have declared no conﬂicts of interest.
references
1. Freedman A. Follicular lymphoma: 2011 update on diagnosis and management.
Am J Hematol 2011; 86: 768–775.
2. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission
tomography for response assessment of lymphoma: consensus of the Imaging
Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol
2007; 25: 571–578.
3. Cheson BD, Pﬁstner B, Juweid ME et al. Revised response criteria for malignant
lymphoma. J Clin Oncol 2007; 25: 579–586.
4. Meignan M, Gallamini A, Haioun C et al. Report on the Second International
Workshop on interim positron emission tomography in lymphoma held in Menton,
France, 8–9 April 2010. Leuk Lymphoma 2012; 51: 2171–2180.
5. Tsukamoto N, Kojima M, Hasegawa M et al. The usefulness of (18)F-
ﬂuorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a
comparison of (18)F-FDG-PET with (67)gallium scintigraphy in the evaluation of
lymphoma: relation to histologic subtypes based on the World Health
Organization classiﬁcation. Cancer 2007; 110: 652–659.
6. Elstrom R, Guan L, Baker G et al. Utility of FDG-PET scanning in lymphoma by
WHO classiﬁcation. Blood 2003; 101: 3875–3876.
7. Wohrer S, Jaeger U, Kletter K et al. 18F-ﬂuoro-deoxy-glucose positron emission
tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading.
Ann Oncol 2006; 17: 780–784.
8. Le Dortz L, De Guibert S, Bayat S et al. Diagnostic and prognostic impact of
18F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging 2010; 37:
2307–2314.
9. Wirth A. PET for follicular lymphoma: a work in progress! Leuk Lymphoma 2007;
48: 1463–1464.
10. Janikova A, Bolcak K, Pavlik T et al. Value of [18F]ﬂuorodeoxyglucose positron
emission tomography in the management of follicular lymphoma: the end of a
dilemma?. Clin Lymphoma Myeloma 2008; 8: 287–293.
11. Karam M, Novak L, Cyriac J et al. Role of ﬂuorine-18 ﬂuoro-deoxyglucose
positron emission tomography scan in the evaluation and follow-up of patients
with low-grade lymphomas. Cancer 2006; 107: 175–183.
12. Blum RH, Seymour JF, Wirth A et al. Frequent impact of [18F]ﬂuorodeoxyglucose
positron emission tomography on the staging and management of patients with
indolent non-Hodgkin’s lymphoma. Clin Lymphoma 2003; 4: 43–49.
13. Trotman J, Fournier M, Lamy T et al. Positron emission tomography-computed
tomography (PET-CT) after induction therapy is highly predictive of patient
outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial
participants. J Clin Oncol 2011; 29: 3194–3200.
14. Dupuis J, Berriolo-Riedinger A, Julian A et al. Impact of [18F]ﬂuorodeoxyglucose
positron emission tomography response evaluation in patients with high-tumor
burden follicular lymphoma treated with immunochemotherapy: a prospective
study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS.
J Clin Oncol 2012; 30: 4317–4322.
15. Federico M, Luminari S, Dondi A et al. R-Cvp Vs R-Chop Vs R-Fm for the initial
treatment of patients with advanced stage follicular lymphoma: preliminary
results of Foll05 Iil trial. Ann Oncol 2011; 22: 128–128.
16. Barosi G, Carella A, Lazzarino M et al. Management of nodal indolent (non-
marginal-zone) non-Hodgkin’s lymphomas: practice guidelines from the Italian
Society of Hematology, Italian Society of Experimental Hematology and Italian
Group for Bone Marrow Transplantation. Haematologica 2005; 90: 1236–1257.
17. Cheson BD, Horning SJ, Coifﬁer B et al. Report of an international workshop to
standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored
International Working Group. J Clin Oncol 1999; 17: 1244.
18. Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international
prognostic index. Blood 2004; 104: 1258–1265.
19. Landis JR, Koch GG. The measurement of observer agreement for categorical
data. Biometrics 1977; 33: 159–174.
20. Bishu S, Quigley JM, Bishu SR et al. Predictive value and diagnostic accuracy of
F-18-ﬂuoro-deoxy-glucose positron emission tomography treated grade 1 and 2
follicular lymphoma. Leuk Lymphoma 2007; 48: 1548–1555.
21. Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s
lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 2004; 22:
1454–1459.
22. Federico M, Bellei M, Marcheselli L et al. Follicular lymphoma international
prognostic index 2: a new prognostic index for follicular lymphoma developed by
the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;
27: 4555–4562.
23. Safar V, Dupuis J, Itti E et al. Interim [18F]ﬂuorodeoxyglucose positron emission
tomography scan in diffuse large B-cell lymphoma treated with anthracycline-
based chemotherapy plus rituximab. J Clin Oncol 2012; 30: 184–190.
original articles Annals of Oncology
 | Luminari et al. Volume 24 | No. 8 | August 2013
 at U
niversitÃ degli Studi di M
odenae Reggio Emilia on December 9, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
